Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Castle Biosciences (CSTL) Other financing activities (2021)

Castle Biosciences' Other financing activities history spans 1 years, with the latest figure at $336000.0 for Q1 2021.

On a quarterly basis, Other financing activities changed N/A to $336000.0 in Q1 2021 year-over-year; TTM through Dec 2021 was $336000.0, a N/A change, with the full-year FY2021 number at $336000.0, changed N/A from a year prior.
Other financing activities hit $336000.0 in Q1 2021 for Castle Biosciences.
Over the last five years, Other financing activities for CSTL hit a ceiling of $336000.0 in Q1 2021 and a floor of $336000.0 in Q1 2021.